TickerFacts.

Company research / ICCC

Immucell Corp (ICCC)

Build a valuation ↗↓ Download CSV

SEC name IMMUCELL CORP /DE/ · CIK 0000811641 · Nasdaq · In Vitro & In Vivo Diagnostic Substances

  • Sector Manufacturing
  • Incorporated DE
  • Fiscal year ends Dec 31

For the year ended 2025-12-31, Immucell Corp reported revenue of $27.64M. Revenue grew 4.3% from the prior annual period. Over the twelve months to 2026-06-30, revenue was $30.68M.

Key ratios (year ended 2025-12-31)

41.4%
Gross margin
6.0%
Operating margin
-3.8%
Net margin
-3.8%
Return on year-end equity
4.3%
Revenue growth (YoY)

Beyond the statements

Follow the company.

Explore new filings, reported insider transactions and company relationships.

Open company research ↗

Latest selected filing: Form 8-K (current report) · 2026-10-13

Annual financials

Annual flows and balances are grouped by their actual period end. Select a figure to open its SEC filing. n/a means a matching observation is unavailable. Free cash flow is operating cash flow minus capital expenditures, and EBITDA is operating income plus depreciation and amortization, for the same period, computed by TickerFacts.

The first column covers the twelve months to 2026-06-30 from the latest quarterly report: flows are the last fiscal year plus this year to date minus the same months a year earlier, and balances are as of that date. Per-share figures are annual only.

Period endedTTM to
2026-06-30		2025-12-312024-12-312023-12-312022-12-312021-12-312020-12-312019-12-312018-12-312017-12-312016-12-31
Revenue$30.68M$27.64M$26.49M$17.47M$18.57M$19.24M$15.34M$13.72M$10.99M$10.43Mn/a
Cost of Revenue$18.31M$16.20M$18.55M$13.60M$10.92M$10.59M$8.48M$6.98M$5.79M$5.21M$4.12M
Gross Profit$12.37M$11.45M$7.94M$3.87M$7.65M$8.66M$6.86M$6.74M$5.19M$5.22M$5.42M
R&D Expense$1.89M$3.04M$3.90M$4.39M$4.49M$4.17M$4.35M$3.69M$3.52M$2.05M$1.24M
Operating Income$3.87M$1.65M-$1.64M-$5.75M-$2.30M$257.4K-$1.38M-$953.9K-$1.45M-$242.8K$890.2K
Depreciation & Amortization$2.42M$2.78M$2.73Mn/an/an/an/an/an/an/an/a
EBITDA$6.28M$4.43M$1.09Mn/an/an/an/an/an/an/an/a
Net Income$787.4K-$1.04M-$2.16M-$5.77M-$2.49M-$78.3K-$1.02M-$1.30M-$2.32M-$168.1K$508.4K
EPS (Diluted)n/a-$0.12-$0.26-$0.75-$0.32-$0.01-$0.14-$0.19-$0.42-$0.03$0.12
Total Assets$46.63M$42.53M$45.10M$43.81M$44.86M$44.47M$40.35M$38.69M$32.73M$34.30M$24.70M
Total Liabilities$15.26M$15.48M$17.58M$18.82M$14.48M$11.89M$12.08M$9.70M$10.99M$10.70M$4.98M
Long-Term Debt$8.30M$9.10Mn/an/a$10.23M$812.2K$9.50M$8.42M$9.27M$8.96Mn/a
Shareholders' Equity$31.37M$27.06M$27.52M$24.99M$30.38M$32.58M$28.27M$28.99M$21.74M$23.59M$19.72M
Cash & Equivalents$8.86M$3.81M$3.76M$978.7K$5.79M$10.19M$6.95M$6.29M$2.52M$3.80M$5.15M
Operating Cash Flow$5.89M$2.48M$357.9K-$4.67M-$1.54M$954.2K$1.32M$233.5K-$373.4K$1.18M-$222.3K
Capital Expenditures$1.68M$1.25M$465.7K$1.89M$3.98M$2.61M$4.07M$1.39M$2.03M$17.76M$3.59M
Free Cash Flow$4.21M$1.22M-$107.8K-$6.57M-$5.52M-$1.65M-$2.76M-$1.16M-$2.40M-$16.58M-$3.81M
Shares Outstanding9.08M9.05M8.98M7.75M7.75M7.74M7.22M7.21M5.57M5.48M4.85M
Weighted Average Diluted Sharesn/a9.03M8.17M7.75M7.75M7.59M7.21M6.82M5.49M4.95M4.34M
EPS (Basic)n/a-$0.12-$0.26-$0.75-$0.32-$0.01-$0.14-$0.19-$0.42-$0.03$0.12

Price chart

Chart and quotes by TradingView. Exchange coverage and delays vary.

Open chart on TradingView